Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.
You may also be interested in...
Copaxone Growth Helps Teva Offset Declining Generics Business
Strong sales for the multiple sclerosis therapy eased the impact of $100 mil. decline in U.S. generics revenue.
Copaxone Growth Helps Teva Offset Declining Generics Business
Strong sales for the multiple sclerosis therapy eased the impact of $100 mil. decline in U.S. generics revenue.
Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal
Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.